De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Bionano Genomics Beheer

Beheer criteriumcontroles 3/4

De CEO Bionano Genomics' is Robert Holmlin, benoemd in Jan2011, heeft een ambtstermijn van 13.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.25M, bestaande uit 47.7% salaris en 52.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.031% van de aandelen van het bedrijf, ter waarde $ 12.01K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 5.4 jaar.

Belangrijke informatie

Robert Holmlin

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	47.7%
Dienstverband CEO	13.8yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)

Aug 29

Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Earnings Pushing Shares 31% Lower

May 09

Bionano Genomics, Inc. (NASDAQ:BNGO) Analysts Just Trimmed Their Revenue Forecasts By 9.0%

Mar 14

Bionano Genomics: Little Clinical Utility And A Whole Lot Of Burn

Oct 18

Bionano stock dips amid launch of Bionano Laboratories for optical genome mapping tests

Sep 23

Analyse CEO-vergoeding

Hoe is Robert Holmlin's beloning veranderd ten opzichte van Bionano Genomics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$204m
Mar 31 2024	n/a	n/a	-US$227m
Dec 31 2023	US$1m	US$599k	-US$232m
Sep 30 2023	n/a	n/a	-US$227m
Jun 30 2023	n/a	n/a	-US$147m
Mar 31 2023	n/a	n/a	-US$140m
Dec 31 2022	US$3m	US$544k	-US$133m
Sep 30 2022	n/a	n/a	-US$117m
Jun 30 2022	n/a	n/a	-US$106m
Mar 31 2022	n/a	n/a	-US$92m
Dec 31 2021	US$8m	US$484k	-US$72m
Sep 30 2021	n/a	n/a	-US$61m
Jun 30 2021	n/a	n/a	-US$51m
Mar 31 2021	n/a	n/a	-US$41m
Dec 31 2020	US$708k	US$376k	-US$41m
Sep 30 2020	n/a	n/a	-US$37m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$899k	US$404k	-US$30m
Sep 30 2019	n/a	n/a	-US$28m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$3m	US$390k	-US$18m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$22m
Dec 31 2017	US$605k	US$379k	-US$23m

Compensatie versus markt: De totale vergoeding ($USD 1.25M ) Robert } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).

Compensatie versus inkomsten: De vergoeding van Robert is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Robert Holmlin (56 yo)

13.8yrs

Tenure

US$1,254,658

Compensatie

Dr. Robert Erik Holmlin, Ph D., M.B.A. has been the Chief Executive Officer and President of BioNano Genomics, Inc. (alternatively BioNanomatrix, Inc.) since January 12, 2011 and served as its Secretary &...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Holmlin	President	13.8yrs	US$1.25m	0.031% $ 11.2k
Mark Oldakowski	Chief Operating Officer	6.9yrs	US$884.78k	0.022% $ 8.2k
Alka Chaubey	Chief Medical Officer	4.2yrs	US$864.78k	0.053% $ 19.3k
Mark Adamchak	VP of Accounting & Controller	6.3yrs	geen gegevens	geen gegevens
Jonathan Dixon	General Counsel & Secretary	2.6yrs	geen gegevens	0.021% $ 7.7k
Stanislas Marin	Vice President of Global Sales	2.8yrs	geen gegevens	geen gegevens
Sheila Purim	Vice President of Global Marketing	less than a year	geen gegevens	geen gegevens
Donna Polizio	Global Head of Market Access	1.9yrs	geen gegevens	geen gegevens
Cory Kreeck	Global Head of People Operations	2.8yrs	geen gegevens	geen gegevens
Klint Rose	Head of Research & Development	less than a year	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BNGO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Holmlin	President	13.8yrs	US$1.25m	0.031% $ 11.2k
Christopher Twomey	Independent Director	6.3yrs	US$72.75k	0.0075% $ 2.7k
David Barker	Independent Director	14.4yrs	US$97.75k	0.0068% $ 2.5k
Albert Luderer	Independent Chairman	13yrs	US$77.75k	0% $ 0
Hannah Mamuszka	Independent Director	4.4yrs	US$60.25k	0.0076% $ 2.8k
Kristiina Vuori	Independent Director	5.4yrs	US$70.25k	0% $ 0
Yvonne Linney	Independent Director	4.4yrs	US$57.75k	0% $ 0
Vincent Wong	Independent Director	2.8yrs	US$62.75k	0% $ 0
Aleksandar Rajkovic	Independent Director	2.7yrs	US$57.75k	0% $ 0

5.4yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BNGO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Bionano Genomics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. Announces Executive Changes

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Independent Director exercised options and sold US$65k worth of stock

Recent updates

Bionano Genomics, Inc. Expects to Reduce its Overall Headcount by Approximately 84 Employees

Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)

Consensus EPS estimates upgraded to US$1.30 loss

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bionano Genomics, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Bionano Genomics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Bionano Genomics, Inc. Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma

Bionano Genomics Receives Non-Compliance Letter from the Nasdaq Stock Market

Bionano Genomics, Inc. has completed a Follow-on Equity Offering in the amount of $9.994188 million.

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000001 million.

Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics

Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting

Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Shareholder dilution

Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$6.81 loss per share (vs US$4.59 loss in FY 2022)

Bionano Genomics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bionano Genomics, Inc. announced that it has received $35 million in funding

Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Consensus EPS estimates fall by 20%

Bionano Announces Full Commercial Release of the Stratys™? System for High Throughput Optical Genome Mapping

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing

Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via™ Software for Ogm Data Analysis in Constitution Genetic Disease Research

Price target increased by 10% to US$12.33

Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Bionano Genomics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

New minor risk - Market cap size

Bionano Genomics, Inc. Announces the Publication of Study Detailing the Challenges Associated with the Detection and Interpretation of Causal Variants in Mendelian Disease

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Bionano Genomics, Inc. Announces Executive Changes

Price target decreased by 17% to US$35.40

Bionano Genomics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Bionano Genomics, Inc. Announces the Stratys System for OGM and VIA™? Software for Hematologic Malignancies

Bionano Genomics, Inc.(NasdaqCM:BNGO) dropped from Russell Small Cap Comp Value Index

Bionano Genomics, Inc. Announces Peer-Reviewed Publication on the Utility of Combining Ogm and A 523-Gene Ngs Panel for Standard Evaluation of Myeloid Cancers

Bionano Announces Commercial Release of New Kits for Its Ionic System Featuring New Chemistry for Nucleic Acid Extraction from Ffpe and Tumor Tissue

Bionano Genomics Receives Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price Requirement

Price target decreased by 14% to US$3.68

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Earnings Pushing Shares 31% Lower

Bionano Genomics, Inc. to Report Q1, 2023 Results on May 09, 2023

Bionano Genomics, Inc. (NASDAQ:BNGO) Analysts Just Trimmed Their Revenue Forecasts By 9.0%

Full year 2022 earnings: EPS misses analyst expectations

Bionano Genomics, Inc. Launches Next-Generation Versions of Its Reagent Kits and Chip Consumable, Along with Updates to Its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Price target decreased to US$7.38

Bionano Genomics, Inc. Announces Publication of Study Utilizing Optical Genome Mapping

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.074 loss in 3Q 2021)

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Hamilton and Bionano Genomics, Inc. Announce Commercial Availability of World's First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM

Bionano Genomics: Little Clinical Utility And A Whole Lot Of Burn

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing That WGS Identified Only 63% of Structural Variations That OGM Detected in Liver Cancer

Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories

Bionano stock dips amid launch of Bionano Laboratories for optical genome mapping tests

Bionano Genomics, Inc. Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss

Bionano Genomics Announces Publication of Study Demonstrating Utility of OGM as Part of Comprehensive Workflow for Quality Evaluation of Human Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity